Denali’s Hunter syndrome therapy gets priority review; LENZ inks Canada dealnews2025-07-07T14:46:50+00:00July 7th, 2025|Endpoints News|
Cloudbreak’s shares stumble in Hong Kong debut; Sinovac squares off against activistnews2025-07-03T14:27:11+00:00July 3rd, 2025|Endpoints News|
Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an assetnews2025-07-02T14:34:02+00:00July 2nd, 2025|Endpoints News|
Broad Institute conducts layoffs as it preps for cuts in federal funding; Dyne’s financingnews2025-07-01T15:29:05+00:00July 1st, 2025|Endpoints News|
INmune Bio’s Alzheimer’s drug fails Phase 2; BridgeBio sells some ATTR-CM royaltiesnews2025-06-30T15:09:25+00:00June 30th, 2025|Endpoints News|
BioCryst sells Orladeyo business in Europe; UCB gets a Phase 3 win for Finteplanews2025-06-27T14:47:00+00:00June 27th, 2025|Endpoints News|
Edgewise details pivotal plans in Becker muscular dystrophy; Kymera’s $250M offeringnews2025-06-26T15:08:30+00:00June 26th, 2025|Endpoints News|
Arbutus regains rights to hepatitis B asset in China; Forte’s $75M offeringnews2025-06-25T15:04:34+00:00June 25th, 2025|Endpoints News|
ArriVent plots next steps for lung cancer drug; Neuron23’s $96.5M raisenews2025-06-24T14:57:43+00:00June 24th, 2025|Endpoints News|
Formation Bio’s up to €545M licensing deal with Sanofi; Otsuka, Harbour BioMed team upnews2025-06-23T15:15:50+00:00June 23rd, 2025|Endpoints News|
